



## 2013 NCDEU Pharma Pipelines

**Session Date: Tuesday, May 28th 3:45pm- 6:00pm**

- *Safety, Pharmacokinetic and Positron Emission Tomography Evaluation of Serotonin and Dopamine Transporter Occupancy Following Multiple-dose Administration of the Triple Monoamine Reuptake Inhibitor BMS-820836, **Bristol-Myers Squibb***
- *Early Development of ALKS 3831: A Novel Drug Candidate for the Treatment of Schizophrenia, **Alkermes, Inc.***
- *PH 10 May Be A New Rapidly Acting Intranasally Administered Antidepressant, The Medical Research Network*
- *Dose Response Analysis of Lisdexamfetamine Dimesylate for Treatment of Binge Eating Disorder, **Lindner Center of HOPE***
- *Suvorexant: Orexin Receptor Antagonism and Insomnia, Merck*
- *Pharmacology, Safety and Efficacy in Major Depressive Disorder of CX-157, a Reversible Inhibitor of Monoamine Oxidase A, **CNS at PPDi***
- *A Randomized, Double-Blind, Study of Vortioxetine versus Agomelatine in Adults with Major Depressive Disorder (MDD) Switched after Inadequate Response to SSRI or SNRI Treatment, **H. Lundbeck A/S***
- *Treatment of Depression with OnabotulinumtoxinA: A Randomized, Double-Blind, Placebo Controlled Trial, **Chevy Chase Cosmetic Center***
- *Gepirone-ER: Effective Treatment of Major Depression and Accompanying Sexual Dysfunction, **Fabre Kramer Pharmaceuticals, Inc.***
- *REFRESH: A Phase2 RP 5063 Efficacy and Safety in Schizophrenia and Schizoaffective Disorder, **Reviva Pharmaceuticals***
- *Broad Therapeutic Potential for ITI-007 and IC200131, **Intra-Cellular Therapies, Inc.***
- *EVP-6124, An Alpha-7 Nicotinic Partial Agonist, Produces Positive Effects on Cognition, and Clinical Function in Patients with Chronic Schizophrenia on Stable Antipsychotic Therapy, **EnVivo Pharmaceuticals***